Your browser doesn't support javascript.
loading
CD9 and Aryl Hydrocarbon Receptor Are Markers of Human CD19+CD14+ Atypical B Cells and Are Dysregulated in Systemic Lupus Erythematous Disease.
Blevins, Lance K; Khan, D M Isha Olive; Crawford, Robert B; O'Neill, Christine; Bach, Anthony P; Zhou, Jiajun; Karmaus, Peer W; Ang, Dennis C; Thapa, Rupak; Kaminski, Norbert E.
Afiliação
  • Blevins LK; Institute of Integrative Toxicology, Michigan State University, East Lansing, MI.
  • Khan DMIO; Institute of Integrative Toxicology, Michigan State University, East Lansing, MI.
  • Crawford RB; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI.
  • O'Neill C; Institute of Integrative Toxicology, Michigan State University, East Lansing, MI.
  • Bach AP; Atrium Health Wake Forest Baptist School of Medicine, Winston Salem, NC.
  • Zhou J; Institute of Integrative Toxicology, Michigan State University, East Lansing, MI.
  • Karmaus PW; Institute of Integrative Toxicology, Michigan State University, East Lansing, MI.
  • Ang DC; Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI.
  • Thapa R; National Institute of Environmental Health Sciences, Research Triangle Park, NC.
  • Kaminski NE; Atrium Health Wake Forest Baptist School of Medicine, Winston Salem, NC.
J Immunol ; 2024 Aug 30.
Article em En | MEDLINE | ID: mdl-39212542
ABSTRACT
Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor whose expression regulates immune cell differentiation. Single-cell transcriptomic profiling was used to ascertain the heterogeneity of AHR expression in human B cell subpopulations. We identified a unique population of B cells marked by expression of AHR, CD9, and myeloid genes such as CD14 and CXCL8. Results were confirmed directly in human PBMCs and purified B cells at the protein level. TLR9 signaling induced CD14, CD9, and IL-8 protein expression in CD19+ B cells. CD14-expressing CD9+ B cells also highly expressed AHR and atypical B cell markers such as CD11c and TBET. In patients with active lupus disease, CD14+ and CD9+ B cells are dysregulated, with loss of CD9+ B cells strongly predicting disease severity and demonstrating the relevance of CD9+ B cells in systemic lupus erythematosus and autoimmune disease.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article